4'-Methyl-α-pyrrolidinohexiophenone

From Wikipedia, the free encyclopedia

Jump to: navigation, search
4'-Methyl-α-pyrrolidinohexiophenone
MPHP structure.png
Systematic (IUPAC) name
(RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone
Clinical data
Legal status
Identifiers
CAS Number 34138-58-4
PubChem CID 6423085
ChemSpider 4928584
Chemical data
Formula C17H25NO
Molar mass 259.385 g/mol
Chirality 1 : 1 mixture (racemate)

4'-Methyl-α-pyrrolidinohexiophenone or MPHP is a stimulant compound which has been reported as a novel designer drug.[1][2][3] It is closely related to pyrovalerone, being simply its chain-lengthened homologue. In the pyrrolidinophenone series, stimulant activity is maintained so long as the positions of the aryl, ketone and pyrrolidinyl groups are held constant, while the alkyl backbone can be varied anywhere between three to as many as seven carbons,[4] with highest potency usually seen with the pentyl or isohexyl backbone, and a variety of substituents are tolerated on the aromatic ring.[5]

In 2010 a group of researchers from the Institute of Forensic Medicine, University Hospital Jena, Germany concluded that MPHP can lead to serious poisoning with toxic liver damage and rhabdomyolysis.[6]

Legality[edit]

Sweden's public health agency suggested to classify MPHP as narcotic on June 1, 2015.[7]

See also[edit]

References[edit]

  1. ^ Springer, D; Peters, FT; Fritschi, G; Maurer, HH (2003). "New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry". Journal of Chromatography B 789 (1): 79–91. doi:10.1016/S1570-0232(03)00043-6. PMID 12726846. 
  2. ^ Peters, FT; Dragan, CA; Kauffels, A; Schwaninger, AE; Zapp, J; Bureik, M; Maurer, HH (2009). "Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis". Journal of analytical toxicology 33 (4): 190–7. doi:10.1093/jat/33.4.190. PMID 19470220. 
  3. ^ "Acute poisoning involving the pyrrolidinophenone-type designer drug 4'-methyl-alpha-pyrrolidinohexanophenone (MPHP)". Forensic Sci. Int. 208 (1-3): e20–5. May 2011. doi:10.1016/j.forsciint.2011.02.026. PMID 21444164. 
  4. ^ GB patent 1149366, "α-substituted-ketones and processes for their preparation." 
  5. ^ Meltzer, PC; Butler, D; Deschamps, JR; Madras, BK (2006). "1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors". Journal of Medicinal Chemistry 49 (4): 1420–32. doi:10.1021/jm050797a. PMC 2602954. PMID 16480278. 
  6. ^ Sauer, C.; Hoffmann, K.; Schimmel, U.; Peters, F. T. (2011). "Acute poisoning involving the pyrrolidinophenone-type designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP)". Forensic Science International 208 (1–3): e20–e25. doi:10.1016/j.forsciint.2011.02.026. PMID 21444164. 
  7. ^ "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Retrieved 29 June 2015.